Challenge Works, a not-for-profit enterprise owned by Nesta, the UK's innovation agency for social good, has launched a £7.5 million (~$10 million) international program to incentivize the use of AI-based approaches to transform therapeutic discovery for the treatment of ALS. This five-year prize will see global multidisciplinary teams compete in a three-phased program to identify, prioritize, and validate high-potential therapeutic targets for ALS. Aside from funding, the prize will also support multidisciplinary teams by providing a wide range of resources, including robust datasets, computational power, technical expertise, and partnership opportunities. Submissions must be received by December 3, 2025.
Learn More.